NeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company, has released promising results from the initial Phase 2 RoAD trial on Sept. 10, 2025. The study showed enhancements in brain-cell connectivity and health, supporting potential treatment benefits. The trial also reported a positive safety profile. NeuroSense, listed on Nasdaq as NRSN, continues to advance its research in improving brain health through innovative therapies.